Unknown

Dataset Information

0

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.


ABSTRACT: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

SUBMITTER: Zeidan AM 

PROVIDER: S-EPMC4299460 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Zeidan Amer M AM   Lee Ju-Whei JW   Prebet Thomas T   Greenberg Peter P   Sun Zhuoxin Z   Juckett Mark M   Smith Mitchell R MR   Paietta Elisabeth E   Gabrilove Janice J   Erba Harry P HP   Tallman Martin S MS   Gore Steven D SD  

British journal of haematology 20140409 3


The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted re  ...[more]

Similar Datasets

| S-EPMC10933698 | biostudies-literature
| S-EPMC6086331 | biostudies-literature
| S-EPMC5884776 | biostudies-literature
| S-EPMC5728469 | biostudies-literature
| S-EPMC3627328 | biostudies-literature
| S-EPMC7658235 | biostudies-literature
| S-EPMC6361844 | biostudies-literature
| S-EPMC4833933 | biostudies-literature
| S-EPMC7115823 | biostudies-literature
| S-EPMC8706301 | biostudies-literature